Pax Neuroscience is focused on the commercialization of biomarker-based clinical laboratory services and products that target clinical depression and other mood disorders due to the serious unmet needs that are well documented, expensive and growing.
Today, the diagnosis of clinical depression is based on a patient’s self-report of symptoms and limited patient observation. Treatment is based on ‘trial and error’.
A major obstacle to the diagnosis, treatment and research on depression and depression therapeutics is the lack of a biological marker.
The Pax solution is a biomarker-based blood test that provides unbiased evidence of depression and treatment-response based on the biology of depression and mechanism of action of antidepressants.
Our breakthrough technology can revolutionize the diagnosis and therapy for a disease that afflicts ~20% of the U.S. population and about 15% of the populations of developed countries.
Our products and services will improve the standard of care and quality of life for patients with depression, and help return people to active, productive lives.